Table 1

Distribution of clinical characteristics by ECOG PS

Clinical characteristicECOG PS 0–1ECOG PS 2
N=195 (%)N=39 (%)
Age, median (range)68 (35-92)73 (43-91)
Age
 <70111 (56.9)17 (43.6)
 ≥7084 (43.1)22 (56.4)
Sex
 Male95 (48.8)20 (51.3)
 Female100 (51.2)19 (48.7)
Smoking status
 Current/former177 (90.8)37 (94.9)
 Never18 (9.2)2 (5.1)
Histology
 Adenocarcinoma150 (76.9)30 (76.9)
 Squamous cell carcinoma25 (12.8)6 (15.4)
 NSCLC NOS20 (10.3)3 (7.7)
Oncogenic driver mutation
 KRAS65 (37.6)16 (45.7)
 Potentially targetable oncogenes*26 (15.0)3 (8.6)
 None identified82 (47.4)16 (45.7)
 N.A.224
Brain metastases
 Absent146 (74.9)24 (61.5)
 Present49 (25.1)15 (38.5)
PD-L1 expression
 ≥90%99 (50.8)17 (43.6)
 50%–89%96 (49.2)22 (56.4)
  • *Including (BRAF, MET, HER2, RET).

  • ECOG PS, Eastern Cooperative Oncology Performance Status; N.A., not available; NSCLC NOS, non–small cell lung cancer not otherwise specified; PD-L1, programmed cell death ligand 1.